Evidence map›Paper›PMID 29882841›Full record

Trial reportNutrients2018

A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D₃ Supplementation.

Sophie De Niet, Monte Coffiner, Stéphanie Da Silva, Bernard Jandrain, Jean-Claude Souberbielle, Etienne Cavalier

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04636086 (Vitamin D Supplementation and Covid-19), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04636086 phase4completednot on this mapstarted 2020, after this paper: background citation

Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study

TypeinterventionalSponsorUniversity of LiegeRan2020 to 2022Enrolled50ConditionsCovid19ArmsCholecalciferol, Placebo
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Oral vitamin DOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Serum vitamin D levels in patients with lung metastases.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Effect of Vitamin DMicroorganisms · 2023
    Article
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sophie De NietClinical Department, Laboratoires SMB SA, 1080 Brussels, Belgium. sdeni@smb.be.
Monte CoffinerClinical Department, Laboratoires SMB SA, 1080 Brussels, Belgium. mcoff@smb.be.
Stéphanie Da SilvaClinical Department, Laboratoires SMB SA, 1080 Brussels, Belgium. sdsil@smb.be.
Bernard JandrainDepartment of Clinical Pharmacology, ATC SA, 4000 Liège, Belgium. bernard.jandrain@atc-pharma.be.
Jean-Claude SouberbielleLaboratoire d'Explorations fonctionnelles, Hôpital Necker-Enfants malades, Paris 75014, France. jean-claude.souberbielle@nck.aphp.fr.
Etienne CavalierDepartment of Clinical Chemistry, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium. Etienne.cavalier@chu.ulg.ac.be.ORCID 0000-0003-0947-2226

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to determine whether a cumulative dose of vitamin D₃ produces the same effects on the serum concentration of 25(OH)D₃ if it is given daily or monthly. This is a monocentric, two-armed, randomized, interventional, open, and parallel study conducted from November 2016 to March 2017 in Belgium. We randomized 60 subjects with vitamin D deficiency to receive 2000 IU vitamin D₃ daily or 50,000 IU monthly. The same cumulative dose of vitamin D₃ was given to each treatment group (150,000 IU). The 25(OH)D₃ serum concentrations from baseline to day 75 were 14.3 ± 3.7 to 27.8 ± 3.9 ng/mL in the monthly group and 14.1 ± 3.4 to 28.8 ± 5.4 ng/mL in the daily group. The mean change versus the baseline level was significantly different between the groups at day 2, 4, 7, and 14 and no longer different from day 25. One day after the intake of vitamin D₃, as expected, serum 25(OH)D₃ and 1,25(OH)₂D₃ increased significantly in the monthly group, whereas they did not change significantly in the daily group. The median time to reach the 20 ng/mL target concentration was significantly different in the two groups, in favor of the monthly regimen (1 day versus 14 days;

Indexed as

Dietary SupplementsAdultBelgiumBiomarkersCalcifediolCholecalciferolDrug Administration ScheduleFemaleFibroblast Growth Factor-23HumansMaleMiddle AgedTime FactorsTreatment OutcomeUp-RegulationVitamin D DeficiencyBiomarkersCalcifediolCholecalciferolFGF23 protein, humanFibroblast Growth Factor-23calcidiolcalcitriolFGF23regimensupplementationvitamin D

Identifiers

PMID29882841
PMCPMC6024703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.